M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy
Chuanfan Zhong, Zining Long, Taowei Yang, Shuo Wang, Weibo Zhong, Feng Hu, Jeremy Yuen‐Chun Teoh, Jianming Lü, Xiangming Mao
Abstract
ratio. Moreover, depletion of circRBM33 significantly increased the response sensitivity to androgen receptor signalling inhibitor (ARSI) therapy, including enzalutamide and darolutamide, in prostate tumours. Our study suggested that the m6A-mediated circRBM33-FMR1 complex can activate mitochondrial metabolism by stabilizing PDHA1 mRNA, which promotes PCa progression, and can attenuate circRBM33 increased ARSI effectiveness in PCa treatment. This newly discovered circRNA may serve as a potential therapeutic target for PCa.
Topics & Concepts
Downregulation and upregulationProstate cancerEnzalutamideBiologyAndrogen receptorCancer researchCell biologyRNACancerBiochemistryGeneGeneticsRNA modifications and cancerCircular RNAs in diseasesRNA Research and Splicing